Analyst Reco. Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
8.98 ^USD	+5.15%		+3.22%	+46.25%

01/04	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT
01/04	Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Starts Solid Biosciences With Outperform Rating	28/03	MT
Barclays Adjusts Price Target on Solid Biosciences to $21 From $8, Maintains Overweight Rating	18/03	MT
Citigroup Starts Coverage on Solid Biosciences With Buy Rating, $16 Price Target	15/03	MT
Piper Sandler Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $20 From $8	14/03	MT
HC Wainwright Adjusts Solid Biosciences' PT to $16 From $9, Maintains Buy Rating	11/03	MT
Solid Biosciences Shares Fall After Surging Thursday; HC Wainwright Starts Coverage With Buy Rating	09/12	MT
HC Wainwright Initiates Solid Biosciences With Buy Rating, Price Target is $9	08/12	MT
Cantor Fitzgerald Initiates Solid Biosciences at Overweight, $5 Price Target	22/23/22	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $8 From $15, Maintains Neutral Rating	11/22/11	MT
Barclays Adjusts Price Target on Solid Biosciences to $8 From $2, Maintains Overweight Rating	11/22/11	MT
SVB Securities Downgrades Solid Biosciences to Market Perform From Outperform, Adjusts Price Target to $1 From $12	17/22/17	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $1 From $2, Maintains Neutral Rating	04/22/04	MT
JPMorgan Upgrades Solid Biosciences to Neutral From Underweight	30/22/30	MT
Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Buy Rating	12/22/12	MT
Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating	19/22/19	MT
SVB Leerink Adjusts Price Target on Solid Biosciences to $12 From $5, Keeps Outperform Rating	28/22/28	MT
Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating	28/22/28	MT
Chardan Research Adjusts Price Target on Solid Biosciences to $7 From $17 on Duchenne Muscular Dystrophy Market Assumptions, Reiterates Buy Rating	28/22/28	MT
SOLID BIOSCIENCES : Chardan Adjusts Price Target on Solid Biosciences to $17 From $20, Maintains Buy Rating	24/21/24	MT
SOLID BIOSCIENCES : Piper Sandler Starts Solid Biosciences at Neutral With $6 Price Target	12/21/12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Analyst Reco.

Filters